Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methdilazine is a first-generation phenothiazine antihistamine with anticholinergic properties. It acts as a histamine H1 receptor antagonist, competing with histamine for binding at H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. This action provides temporary relief from symptoms such as sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Methdilazine is also used to relieve pruritus in various dermatoses and has moderate sedative effects due to its antimuscarinic activity[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methdilazine.